Home  /  Resource Library  /  The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma- a randomized, open-label phase III trial of the European mantle cell lymphoma network

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma- a randomized, open-label phase III trial of the European mantle cell lymphoma network

Results of a study investigating bortezomib combined with rituxiamb, cytarabine and dexamethasone for treatment of relapsed MCL.